相关实验视频

Updated: May 2, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

循环瘤DNA是血管免疫细胞T细胞淋巴瘤反应的生物标志物

Costas Kleanthes Yannakou^1,2, Simon Wu^3,4,5, Karthik Rajah⁶

¹Epworth HealthCare, Melbourne 3002, Australia.

International journal of molecular sciences

|July 29, 2025

概括

使用循环瘤DNA (ctDNA) 监测血管免疫芽细胞T细胞淋巴瘤 (AITL) 显示,IDH2/RHOA突变比DNMT3A/TET2突变更好地显示残留疾病标志物.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

血管免疫原性T细胞淋巴瘤 (AITL) 是一种侵略性的非霍奇金淋巴瘤.
目前的AITL监测严重依赖于放射学方法.
AITL的特点是特定的体质突变 (RHOA,TET2,IDH2,DNMT3A) 和高的治疗前循环瘤DNA (ctDNA).

研究的目的:

调查ctDNA监测对AITL的有用性.
为了比较治疗前AITL组织和ctDNA中的体质突变.
为了将ctDNA突变负载的变化与放射性反应相关联.

主要方法:

从12名AITL患者的治疗前组织和ctDNA中比较体质突变.
分析的ctDNA突变负担随着时间的推移而变化.
与放射性反应相关联的ctDNA数据,包括完全代谢反应 (CMR).

主要成果:

所有配对的治疗前ctDNA和组织样本都有共同的变异.
在获得CMR的患者中,在治疗后的ctDNA中无法检测到IDH2和RHOA变异.
在大多数患者中,DNMT3A和TET2变异在治疗后的ctDNA中仍然可以检测到CMR.

结论:

IDH2/RHOA变种显示出有前途,作为AITL可测量的残留疾病的更可靠标记.
DNMT3A/TET2变种在AITL中评估最小残留疾病时似乎不那么可靠.
ctDNA监测为AITL管理提供了一个潜在的辅助工具.

关键词:

血管免疫芽细胞T细胞淋巴瘤在循环中的瘤DNA.可测量的残留疾病.

更多相关视频

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.